NCT02954991 2024-04-22Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung CancerMirati Therapeutics Inc.Phase 2 Terminated161 enrolled 15 charts